{"denoms":[{"counts":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Complete remission rate is defined as percentage of participants achieving a CR per IWG criteria.","groups":[{"description":"Participants were planned to receive GSK3326595 in combination with 5-Azacitidine in dose escalation cohort during Part 2 of the study.","id":"OG000","title":"Part 2-Dose Escalation: GSK3326595+5-Azacitidine"},{"description":"Participants were planned to receive GSK3326595 in combination with 5-Azacitidine in dose expansion cohort during Part 2 of the study.","id":"OG001","title":"Part 2-Dose Expansion: GSK3326595+5-Azacitidine"}],"populationDescription":"All Treated Population. Data was not collected as no participants were enrolled in Part 2.","reportingStatus":"POSTED","timeFrame":"Up to 3 years and 2 months","title":"Part 2: Complete Remission (CR) Rate","type":"SECONDARY"}